1. Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III
- Author
-
M.J. Reike, M.A. Ingersoll, D.C. Müller, T.C.M. Zuiverloon, T. Strandgaard, A.M. Kamat, S.B. Williams, R. Seiler, T. Todenhöfer, L. Dyrskjøt, R. Nawroth, P. Goebell, B. Schmitz-Dräger, J.P. Sfakianos, J. Meeks, A. Horowitz, P.C. Black, University of British Columbia [Vancouver], Inflammation et immunité des muqueuses - Mucosal Inflammation and Immunity, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), University of Basel (Unibas), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Aarhus University Hospital, Aarhus University [Aarhus], The University of Texas Medical School at Houston, The University of Texas Medical Branch (UTMB), Technische Universität München = Technical University of Munich (TUM), University Hospital Erlangen = Uniklinikum Erlangen, Icahn School of Medicine at Mount Sinai [New York] (MSSM), and Northwestern University Feinberg School of Medicine
- Subjects
MESH: Humans ,Bacillus Calmette-Guerin (BCG) ,MESH: Immunotherapy ,Urology ,[SDV]Life Sciences [q-bio] ,Bladder cancer ,MESH: Non-Muscle Invasive Bladder Neoplasms ,MESH: Adjuvants, Immunologic ,MESH: Neoplasm Invasiveness ,MESH: Urinary Bladder Neoplasms ,MESH: BCG Vaccine ,SDG 3 - Good Health and Well-being ,Oncology ,MESH: Biology ,Immunotherapy ,MESH: Neoplasm Recurrence, Local ,MESH: Administration, Intravesical - Abstract
International audience; Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.
- Published
- 2022
- Full Text
- View/download PDF